INSULIN BASALOG IS ASSOCIATED WITH LOW GLYCEMIC VARIABILITY IN TYPE 2 DIABETES SUBJECTS

Abstract

INTRODUCTION
Basalog is a biosimilar insulin that has been proven to be safe and efficacious, with the added potential to reduce healthcare costs. Glycemic variability (GV) refers to oscillation in blood glucose throughout the day either due to hypoglycaemia or postprandial increments. Continuous glucose monitoring (CGMS) is a useful tool to measure GV. To date, there has been no study describing the glycemic variability of insulin Basalog in type 2 diabetes (T2D) patients.

OBJECTIVE
To describe the glycemic variability of T2D patients on insulin Basalog

METHODOLOGY
A total of 55 T2D patients were recruited in a single centre study. Basalog was added in patients with uncontrolled diabetes on oral hypoglycemic agents. CGMS was started at least 6 weeks following the addition of Basalog. GV was analysed using the EasyGV software that calculated mean blood glucose (MBG), SD, mean amplitude of glycemic excursions (MAGE), average daily risk ratio (ADRR), lability index (LI), J-Index, low blood glucose index (LBGI), high blood glucose index (HBGI), continuous overlapping net glycemic action (CONGA), mean of daily differences (MODD), glycemic risk assessment in diabetes equation (GRADE), mean glucose (M-value) and mean absolute glucose (MAG).

RESULTS
The parameters for glycemic variability were calculated as follows MBG 9.7±3.01, SD 2.6±1.00, MAGE 4.4±1.28, ADRR 24.4±13.94, LI 2.9±1.62, J-Index 52.8±34.23, LBGI 3.0±5.31, HBGI 10.8±10.2, CONGA 8.9±3.02, MODD 2.4±1.08, GRADE 9.0±7.26, M-Value 16.3±22.7 and MAG 1.5±0.42. The calculated coefficient of variation was 26.8%. The M-value showed 74.5% patients to have good control over their blood glucose. Majority of the patients had a low risk of glycemic variability: 72.7% based on LBGI, 65.5% based on HBGI and 41.8% from ADRR.

CONCLUSION
Basalog was demonstrated to have low glycemic variability with lower risk of hypoglycaemia and postprandial hyperglycaemia.